GLP-1s before surgery: the aspiration-risk guidance, explained
Last updated: October 27, 2026 · 8 min read · By the Grey Peptides Editorial Board
- GLP-1 drugs slow stomach emptying, so food can still be in the stomach after a normal fast, and under anaesthesia it can be inhaled. Reports of this are rare, and the studies show more food left in the stomach rather than more aspiration.
- Advice changed in 2024: the main US societies moved from holding the drug for a week to continuing it for most people, with a 24-hour liquid diet for those at higher risk. UK and Australian guidance also say continue.
- The drug labels do not tell patients to stop; they say to tell your surgical and anaesthesia team you take it. Never stop or change a prescribed drug on your own; the decision belongs to your team.
Why anaesthetists worry about GLP-1 drugs
Before general anaesthesia or deep sedation, patients follow fasting instructions. The concern is retained stomach contents, which at endoscopy or under general anaesthesia can be complicated by pulmonary aspiration, stomach contents entering the lungs 1 2.
GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) and liraglutide, slow the emptying of the stomach; a 2024 review says this helps limit blood sugar rises after meals, that the effect shows tachyphylaxis (it wanes) with prolonged treatment, and that it is limited in people whose stomachs already emptied slowly before treatment 1. The labels record rare postmarketing reports of aspiration in patients who had food left in the stomach despite reportedly following fasting instructions 2.
What the labels say
Each of the four main US semaglutide and tirzepatide injection labels now carries a warning headed 'Pulmonary Aspiration During General Anesthesia or Deep Sedation' 2 3. Wegovy's says the drug delays gastric emptying and that there have been rare postmarketing reports of aspiration in patients on GLP-1 drugs having elective procedures, who had food left in the stomach despite reportedly following fasting instructions 2. It then says something important: available data are insufficient to inform recommendations to reduce the risk, including whether changing fasting rules or temporarily stopping the drug would reduce retained stomach contents 2.
The instruction the labels do give is simple: patients should tell their healthcare providers about any planned surgery or procedure if they are taking the drug 2 3. The labels do not tell patients to stop beforehand. That is consistent with the guidance that followed.
How the advice changed
In 2023 the American Society of Anesthesiologists' guidance recommended a one-week hold of injectable GLP-1 drugs and a one-day hold of oral ones before surgery 4. The 2024 guidance that replaced it for most patients says stopping is not automatically safer, and that the risk of delayed stomach emptying has to be weighed against the risk of stopping the drug, such as higher blood sugar in people with diabetes 5.
In October 2024, five societies, the ASA, the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity and the Society of American Gastrointestinal and Endoscopic Surgeons, published joint guidance that most patients should continue their GLP-1 drugs before elective surgery 5 6. Patients at the highest risk of significant gastrointestinal side effects should follow a liquid diet for 24 hours before the procedure, the team can adjust the anaesthetic plan and use point-of-care ultrasound right before the procedure to check the stomach, and in rare cases surgery should be delayed in patients whose risk is expected to decrease 5. The ASA's release also said that withholding the drugs only from patients with obesity could amount to bias and should be avoided 5.
Other countries reached similar conclusions in 2025. A UK multidisciplinary consensus recommended that patients continue these drugs, with full risk assessment and techniques to reduce aspiration risk, decided jointly with the patient 7. Australian and New Zealand societies recommended continuing them and advised a 24-hour clear-fluid diet followed by the standard six-hour fast for everyone taking them; they said they could not recommend using the absence of gastrointestinal symptoms to judge risk, nor a stopping period that would return stomach emptying to baseline 8. A further US consensus led by the Society for Perioperative Assessment and Quality Improvement noted how much earlier statements had varied, and set out its own recommendations on medication and fasting times 9.
| Guidance | Continue the drug? | What it adds |
|---|---|---|
| ASA guidance, 2023 (superseded for most patients) | Hold: injectable GLP-1 drugs for one week, oral ones for one day | Replaced in 2024 by guidance that weighs the risk of stopping, such as higher blood sugar in diabetes |
| US multi-society guidance, October 2024 (ASA, AGA, ASMBS, ISPCOP, SAGES) | Yes, for most patients | Assess risk; 24-hour liquid diet for higher-risk patients; adjust anaesthesia; consider gastric ultrasound; in rare cases delay |
| UK multidisciplinary consensus, 2025 | Yes | Full risk assessment and techniques to reduce aspiration risk; shared decision-making |
| Australia and New Zealand (ADS, ANZCA, GESA, NACOS), 2025 | Yes | 24-hour clear-fluid diet then standard 6-hour fast for all patients on these drugs |
| US labels for semaglutide and tirzepatide | No instruction to stop | Warn of rare aspiration reports; data insufficient to say whether stopping or longer fasting helps; tell the team about the drug |
What the evidence actually shows
The research pattern is consistent: more food left in the stomach, but no clear rise in aspiration. A meta-analysis of 23 observational studies, covering 262,018 patients having upper gastrointestinal endoscopy, found residual gastric contents about 4.5 times as common in GLP-1 users, and procedures stopped early about 4.5 times as often, but no significant difference in aspiration pneumonia 10. A scoping review found that seven of eight studies comparing users and non-users reported significantly more residual contents in users (19% to 56% against 5% to 20%), that the three studies looking at aspiration found no significant difference, and that all the studies but one case report included patients with other risk factors, such as diabetes, reflux, sleep apnoea or other drugs that slow the stomach 11.
The US guidance focuses on identifying the patients at highest risk rather than stopping the drug for everyone 5. The meta-analysis's 23 studies were all observational 10, and the labels say data are insufficient to guide prevention 2.
Who is at higher risk
The multi-society guidance points to the situations in which delayed stomach emptying is most likely: the dose-escalation phase early in treatment, which the ASA says typically lasts four to eight weeks, higher doses, and gastrointestinal symptoms such as nausea, vomiting or constipation, and conditions that slow the stomach, such as Parkinson's disease 5; reporting on the guidance also lists weekly versus daily dosing among the factors to weigh 4. The 2024 review notes that little is known about the effect of diabetes itself, without the drug, on retained stomach contents 1, and the scoping review lists other contributors, from reflux to medicines such as opioids 11. Australian and New Zealand guidance, by contrast, does not rely on the absence of symptoms 8.
Endoscopy and colonoscopy
Much of the evidence comes from endoscopy, where the doctor can see the stomach directly. In the meta-analysis, endoscopies were stopped early about 4.5 times as often in GLP-1 users; residual contents were less common when the upper endoscopy was done on the same day as a colonoscopy 10.
The multi-society guidance covered endoscopy as well as surgery, and the same principles apply: most patients can continue, and those at higher risk may be asked to follow a liquid diet the day before 5 6. Ask your endoscopy unit what it wants you to do.
If you are told to pause: restarting safely
Some teams still ask some patients to hold a dose. If that happens, ask exactly when to take the last dose and when to restart, because the labels have specific rules for missed doses that differ by drug. Wegovy's label says that if two or more consecutive weekly doses are missed, dose escalation should be restarted at a lower dosage to reduce the risk of gastrointestinal side effects 2. Zepbound's says a missed dose can be taken within four days (96 hours); after that it should be skipped and the next dose taken on the usual day 3. A pause that runs to two or more weekly doses therefore may not mean simply picking up where you left off; your prescriber decides how to restart.
Questions to ask before a procedure
The single most useful step is the one the labels name: tell the surgeon, anaesthetist or endoscopist, well in advance, that you take a GLP-1 drug, which one, what dose and when you last increased it 2. Then ask:
- Should I keep taking my medicine as usual, and if not, when exactly should I take my last dose and restart?
- Do you want me to follow a liquid or clear-fluid diet the day before, and from what time?
- I have recently started or increased my dose, or I have nausea or bloating: does that change the plan or the date?
- If I have diabetes, what should I do about my other diabetes medicines and blood sugar checks?
Guidance differs between countries and hospitals, and it is the team doing the procedure that decides. Do not stop, skip or change a prescribed drug on your own because of something you read, including here.
A note on research and compounded products
Everything above concerns the approved drugs. People using compounded or research versions of semaglutide or tirzepatide should tell their team exactly what they take, including the dose they believe they are taking. Our guide to compounded, branded and research tirzepatide explains the differences, and our GLP-1 transition hub covers switching and stopping safely under supervision.
Frequently asked questions
Should I stop Ozempic before surgery?
Not on your own. Since October 2024, US multi-society guidance says most patients can continue GLP-1 drugs before elective surgery, with extra precautions for those at higher risk. Tell your surgical and anaesthesia team you take it and follow their instructions.
Why do GLP-1 drugs matter for anaesthesia?
They slow stomach emptying, so food can remain in the stomach after a normal fast. Under anaesthesia or deep sedation, retained contents can be inhaled into the lungs; the labels describe postmarketing reports as rare.
What does a 24-hour liquid diet mean before surgery?
Some guidance advises patients at higher risk to have only liquids for the day before a procedure, then follow the usual fasting rules. Your team will say whether it applies to you and what liquids are allowed.
Do GLP-1 drugs increase aspiration risk?
Studies show they make leftover stomach contents more common, but a meta-analysis of endoscopy studies found no significant increase in aspiration pneumonia. The labels say data are insufficient to know how best to reduce the risk.
Related on Grey Peptides
Sources
- Jalleh, R. J., et al. (2024). Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab, 110(1), 1-15. PMID: 39418085
- Novo Nordisk. Wegovy (semaglutide) US prescribing information, sections 2.4 and 5.10 (DailyMed set ee06186f, version 19, effective June 18, 2026); read October 27, 2026. Ozempic injection (set adec4fd2, version 20, effective June 1, 2026) carries the same warning as section 5.10. DailyMed
- Eli Lilly. Zepbound (tirzepatide) US prescribing information, sections 2.3 and 5.9 (DailyMed set 487cd7e7, version 40, effective August 28, 2026); read October 27, 2026. Mounjaro (set d2d7da5d, version 40, effective August 27, 2026) carries the same warning as section 5.9. DailyMed
- Becker's ASC Review. ASA no longer advises holding GLP-1 patients pre-op: 4 things to know. October 31, 2024 (the 2023 one-week and one-day hold of injectable and oral GLP-1 drugs; factors in the 2024 guidance, including weekly versus daily dosing). Read October 27, 2026.
- American Society of Anesthesiologists. New multi-society clinical practice guidance released (GLP-1 receptor agonists before elective surgery). News release, October 29, 2024 (last updated February 18, 2025). Read October 27, 2026. ASA
- Kindel, T. L., et al. (2025). Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period. Clin Gastroenterol Hepatol, 23(12), 2083-2085. PMID: 39480373
- El-Boghdadly, K., et al. (2025). Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement: A consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association. Anaesthesia, 80(4), 412-424. PMID: 39781571
- Hocking, S. L., et al. (2025). 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists. Anaesth Intensive Care, 53(5), 300-306. PMID: 40814081
- Oprea, A. D., et al. (2025). Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement. Br J Anaesth, 135(1), 48-78. PMID: 40379536
- Baig, M. U., et al. (2025). Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis. Gastrointest Endosc, 101(4), 762-771.e13. PMID: 39694296
- Chang, M. G., et al. (2024). A Scoping Review of GLP-1 Receptor Agonists: Are They Associated with Increased Gastric Contents, Regurgitation, and Aspiration Events? J Clin Med, 13(21). PMID: 39518474
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead